BerGenBio

BerGenBio ASA - New share capital registered

Bergen 8 December 2023 - Reference is made to the stock exchange announcement by

BerGenBio ASA (the "Company") on 30 November 2023 regarding the final results of

the first exercise period for the warrants ("Warrants") issued in connection

with the rights issue, which resulted in an allocation of 68,156,682 new shares

in the Company ("New Shares") to investors holding Warrants.

The share capital increase pertaining to the New Shares is now registered with

the Norwegian Register of Business Enterprises. After this, the Company's new

registered share capital is NOK 268,868,921.40 divided into 2,688,689,214

shares, each with a nominal value of NOK 0.10.

For further information, please contact:

Martin Olin CEO, BerGenBio ASA

Rune Skeie, CFO, BerGenBio ASA

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including cancer and severe respiratory infections. The

Company is focused on its proprietary lead candidate, bemcentinib, a potentially

first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC

and severe respiratory infections. BerGenBio is based in Bergen, Norway with a

subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange

(ticker: BGBIO). For more information, visit?www.bergenbio.com

This information is published in accordance with the requirements of the Oslo

Rule Book II and is subject to the disclosure requirements pursuant to Section 5

-12 of the Norwegian Securities Trading Act.

AI Terminal